Carnitine chloride instructions for use in ampoules. Carnitine chloride: application in bodybuilding and not only

Instructions for medical use medicinal product

CARNITINE CHLORIDE

Tradename

Carnitine chloride

International non-proprietary name

Carnitine

Dosage form

Solution for injection 10%

1 ml of solution contains

active substance - carnitine chloride 100 mg,

excipient: water for injection.

Description

Clear, colorless or slightly yellowish liquid.

Pharmacotherapeutic group

Metabolics. Antihypoxants. Vitamin preparations.

ATC code A11EA

Pharmacological properties

Pharmacokinetics

Under conditions of intravenous administration, 3 hours after administration, it is not detected in the blood. Easily penetrates into the liver, myocardium, more slowly - into the muscles. Does not bind to plasma proteins and albumin in various mammalian species, including humans. It is excreted by the kidneys, mainly in the form of acyl esters.

Pharmacodynamics

Carnitine chloride refers to drugs that stimulate metabolic processes. It has anabolic, antihypoxic, antithyroid, stimulating fat metabolism, regenerating effect. Belongs to the group of vitamins B (vitamin W - growth vitamin).

Carnitine chloride is involved in various parts of energy metabolism, affects lipid metabolism. The drug restores the alkaline reserve of the blood, does not affect the blood coagulation system, reduces the formation of keto acids, increases the resistance of tissues to the influence of toxic decay products, activates aerobic processes and inhibits anaerobic glycolysis, stimulates and accelerates reparative processes.

It is a cofactor of metabolic processes that provide maintenance of the activity of coenzyme A (CoA). Competitively displacing glucose, it includes a fatty acid metabolic shunt, the activity of which is not limited by oxygen (unlike aerobic glycolysis), therefore it is effective in acute hypoxia of the brain and in other critical conditions. Has a neurotrophic effect. Inhibits the development of apoptosis. Limits the affected area and restores the structure of the nervous tissue.

Increases the secretion and enzymatic activity of digestive juices (gastric and intestinal), improves the absorption of food. Reduces excess body weight and reduces the fat content in the muscles.

Increases the threshold of resistance to physical activity, leads to the elimination of post-exercise acidosis and, as a result, the restoration of performance after prolonged debilitating loads. Increases glycogen stores in the liver and muscles, contributes to its more economical use.

Indications for use

The drug is prescribed alone or as part of complex therapy.

acute disorders cerebral circulation ischemic stroke, transient ischemic attack

dyscirculatory encephalopathy and various traumatic and toxic lesions of the brain

primary (genetic) and secondary carnitine deficiency (including in patients with chronic kidney failure on hemodialysis)

cardiomyopathy, myocarditis, ischemic heart disease (angina pectoris, acute myocardial infarction, post-infarction conditions), cardiogenic shock

in the treatment of cytostatics, especially anthracyclines (as a cardioprotector)

Dosage and administration

The drug is administered intravenously drip slowly (no more than 60 drops per minute!). Before administration, every 100 mg of the drug (1 ml of a 10% solution) is dissolved in 50 ml of isotonic sodium chloride solution or 5% glucose solution.

In the acute period of diseases in the first 3 days, 10-14 mg / kg of body weight of the patient is administered, in the following days - 7 mg / kg of body weight. The general course of treatment is 7-10 days. If necessary, after 10-12 days, a repeated course of 7 mg / kg of body weight is carried out for 3-5 days.

When prescribing the drug in subacute and recovery periods dyscirculatory encephalopathy and various brain lesions, patients are administered 500-1000 mg of carnitine chloride once a day for 3-5 days. If necessary, a second course is prescribed after 12-14 days.

With a secondary deficiency of carnitine during hemodialysis - intravenously, at a dose of 2 g / day after a hemodialysis session.

In acute myocardial infarction, the daily dose is 100-200 mg / kg of body weight in the form of 4 slow intravenous injections or continuous intravenous administration during the first 48 hours, followed by a dose reduction of 2 times. Next, you should switch to oral carnitine.

In cardiogenic shock, intravenous administration should be continued until this state is resolved.

Side effects

allergic reactions (skin itching, skin rash, urticaria, bronchospasm, edema, anaphylactic shock)

muscle weakness

the appearance of pain along the veins

In the case of rapid administration - 80 drops or more per minute, passing with a decrease in the rate of administration.

Contraindications

increased individual sensitivity to the drug

children's and adolescence up to 18 years (the efficacy and safety of carnitine chloride in children with parenteral administration have not been studied)

Drug Interactions

Glucocorticoids contribute to the accumulation of carnitine in tissues (except the liver). The intake of carnitine can increase the content of free valproic acid in the blood serum and thereby potentiate its action even when taking medium therapeutic doses.

Taking excessive doses of choline can reduce the activity of carnitine.

special instructions

The drug is used with caution in patients with aggravated allergic anamnesis. Since carnitine improves the absorption of glucose, it is necessary to control its level in the blood serum in patients with diabetes mellitus.

Pregnancy and lactation

Special studies to study the possibility of using during pregnancy and lactation have not been conducted. When prescribing during these periods, the benefit to the mother and the potential risk to the fetus or child should be carefully weighed. Use during pregnancy is carried out according to strict indications, under close medical supervision.

Features of the effect of the drug on the ability to control vehicle or potentially dangerous mechanisms

Persons who notice muscle weakness after taking carnitine should refrain from driving and potentially dangerous machinery.

Overdose

Symptoms: increased severity of manifestations of side effects.

Treatment: drug withdrawal, symptomatic therapy.

Release form and packaging

10% solution for injection in 5 ml ampoules. 5 ampoules in a blister pack. 2 contour packs together with instructions for medical use in an individual carton box.

Storage conditions

In a place protected from light at a temperature not exceeding +25 0C.

Keep out of the reach of children!

Shelf life

Do not use after the expiry date stated on the package.

Terms of dispensing from pharmacies

On prescription

Carnitine chloride: instructions for use and reviews

Latin name: Carnitine chloride

ATX Code: A16AA

Active substance: carnitine (carnitine)

Producer: Federal State Institution "Russian Cardiology Research and Production Complex" of the Ministry of Health and Social Development of Russia - Experimental production of medical and biological preparations (Russia), Usolye-Sibirsky CPP (Russia), RUE "Belmedpreparaty" (Belarus)

Description and photo update: 24.10.2018

clear, colorless or slightly yellowish solution.

pharmachologic effect"type="checkbox">

pharmachologic effect

Stimulates metabolic processes, participating in various parts of energy metabolism. It has anabolic, antihypoxic and antithyroid effects, activates fat metabolism, stimulates regeneration, increases appetite. Carnitine is a natural substance related to B vitamins. It is a cofactor in metabolic processes that maintain CoA activity. Reduces basal metabolism, slows down the breakdown of protein and carbohydrate molecules. Promotes penetration through mitochondrial membranes and cleavage of long-chain fatty acids (palmitic, etc.) with the formation of acetyl-CoA, which is necessary to ensure the activity of pyruvate carboxylase in the process of gluconeogenesis, the formation of ketone bodies, the synthesis of choline and its esters, oxidative phosphorylation and the formation of ATP. Mobilizes fat (the presence of 3 labile methyl groups) from fat depots. Competitively displacing glucose, it includes a fatty acid metabolic shunt, the activity of which is not limited by oxygen (unlike aerobic glycolysis), and therefore the drug is effective in acute hypoxia (including the brain) and other critical conditions. It has a neurotrophic effect, improves protein and fat metabolism, increased basal metabolism in thyrotoxicosis (being a partial thyroxine antagonist). It restores the alkaline reserve of the blood, does not affect the blood coagulation system, reduces the formation of keto acids, increases the resistance of tissues to the influence of toxic decay products, activates anaerobic glycolysis, has antihypoxic properties, stimulates and accelerates reparative processes.

Pharmacokinetics

3 hours after intravenous administration, it is almost completely eliminated from the blood. Easily penetrates into the liver and myocardium, more slowly - into the muscles. It is excreted by the kidneys mainly in the form of acyl esters.

Indications for use

Treatment of primary and secondary carnitine deficiency in adults.

Secondary carnitine deficiency in adult patients undergoing hemodialysis.

Suspicion of secondary carnitine deficiency in patients undergoing hemodialysis in the following cases:

severe and persistent muscle spasms and/or hypotensive episodes during dialysis;

· energy deficit, which leads to a significant negative impact on the quality of life;

muscle weakness and/or myopathy;

· cardiopathy;

anemia not responding to erythropoietin treatment or requiring high doses of erythropoietin;

loss of muscle mass.

Contraindications

Childhood up to 18 years old.

Hypersensitivity to the components of the drug.

Pregnancy and lactation

In the course of preclinical studies, the teratogenic effect of the drug was not revealed. At the highest dose, 600 mg/kg body weight, animals showed a statistically insignificant increase in the incidence of post-implantation fetal death by early dates pregnancy. The significance of these results for humans is unknown.

Given the serious consequences of carnitine deficiency in a pregnant woman, the risk of treatment interruption for the mother is considered greater than the theoretical risk to the fetus if treatment is continued.

Carnitine is a common ingredient breast milk.

Dosage and administration

Intravenous drip slowly (no more than 60 drops per minute!). Before administration, every 100 mg of the drug (1 ml of a 10% solution) is dissolved in 50 ml of an isotonic sodium chloride solution of 0.9% or 5% glucose solution.

Use in congenital metabolic disorders

During therapy, it is advisable to monitor the levels of carnitine and acyl-carnitine in both plasma and urine.

The required dose depends on the specifics of the congenital metabolic disorder and the severity of the manifestations of the disease.

Secondary carnitine deficiency in patients undergoing hemodialysis

Before starting therapy with the drug, it is desirable to control the level of carnitine in the blood plasma. Secondary carnitine deficiency is diagnosed when the ratio of acylcarnitine to free carnitine in blood plasma is more than 0.4 and / or when the concentration of free carnitine is less than 20 µmol / l.

A dose of 2 g should be administered as a slow intravenous drip at the end of each dialysis session. The overall response should be determined by monitoring plasma levels of acylcarnitine and free carnitine and assessing the patient's condition. Normalization of the carnitine content in muscle tissue and cardiomyocytes occurs approximately 3 months after reaching the normal concentration of carnitine in the blood plasma. If the introduction of carnitine is stopped, its level will certainly begin to decrease again. The need for a repeated saturating course of treatment is determined by quantitative determination of carnitine in blood plasma at regular intervals and by monitoring the patient's condition.

Hemodialysis-supportive therapy

After a saturating course of carnitine administration, a maintenance dose of 1 g of carnitine per day orally is used. On the day of dialysis, the drug is administered intravenously at a dose of 1 g immediately after the completion of the next session.

Children

The drug is contraindicated in children, since there have been no special safety studies of the use of D, L-carnitine in children.

Side effect"type="checkbox">

Side effect

Various mild gastrointestinal disturbances have been observed with long-term oral carnitine use, including transient nausea and vomiting, abdominal pain, and diarrhea. Dose reduction often reduces or eliminates gastrointestinal symptoms. Tolerability must be carefully monitored during the first week of use and after any increase in dose. Intravenous use The drug is usually well tolerated. With rapid administration (80 drops / minute or more), pain may occur along the vein, passing with a decrease in the rate of administration.

Overdose

There have been no reports of carnitine toxicity in overdose. Large doses of the drug may cause diarrhea. Carnitine is easily removed from blood plasma by dialysis.

Carnitine - 100 mg.

Solution for injection 10%. 10 ampoules of 5 ml per pack.

pharmachologic effect

Metabolic.

Pharmacokinetics

After intravenous administration, after 3 hours it disappears from the blood. Easily penetrates into the liver and myocardium, more slowly - into the muscles. It is excreted by the kidneys mainly in the form of acyl esters.

Pharmacodynamics

Carnitine is a metabolic agent. The drug stimulates metabolic processes, participating in various parts of energy metabolism, has anabolic, antihypoxic and antithyroid effects, activates lipid metabolism, stimulates regeneration, increases appetite.

Carnitine is a natural substance related to B vitamins. It is a cofactor in metabolic processes that maintain CoA activity. It reduces basal metabolism, slows down the breakdown of protein and carbohydrate molecules.

Promotes penetration through mitochondrial membranes and cleavage of long-chain fatty acids (including palmitic) with the formation of acetyl-CoA, which is necessary to ensure the activity of pyruvate carboxylase in the process of gluconeogenesis, the formation of ketone bodies, the synthesis of choline and its esters, oxidative phosphorylation and the formation of ATP.

Mobilizes fat (the presence of three labile methyl groups) from fat depots. Competitively displacing glucose, it includes a fatty acid metabolic shunt, the activity of which is not limited by oxygen (unlike aerobic glycolysis), and therefore the drug is effective in conditions of acute hypoxia (including the brain) and other critical conditions.

It has a neurotrophic effect, inhibits apoptosis, limits the affected area and restores the structure of the nervous tissue. Normalizes protein and fat metabolism, increased basal metabolism in hyperthyroidism (being a partial thyroxine antagonist).

The drug restores the alkaline reserve of the blood, does not affect the blood coagulation system, reduces the formation of keto acids, increases the resistance of tissues to the influence of toxic decay products, activates aerobic processes and inhibits anaerobic glycolysis, has antihypoxic properties, stimulates and accelerates reparative processes.

Indications for use Carnitine chloride

Acute disorders of cerebral circulation - ischemic stroke (in acute, subacute and recovery periods), transient ischemic attack - as part of complex therapy, dyscirculatory encephalopathy, traumatic and toxic lesions of the brain.

Contraindications to the use of carnitine chloride

Hypersensitivity to carnitine, age up to 18 years (special studies of use in children have not been conducted).

Carnitine chloride Use in pregnancy and children

Special studies of the use during pregnancy and during breastfeeding have not been conducted. The decision to use should be made, evaluating the ratio of the possible risk to the child and the benefit to the mother.

The use of the drug in children under 18 years of age is contraindicated.

Carnitine chloride side effects

Allergic reactions are possible.

In patients with uremia, muscle weakness is possible.

With rapid administration (80 drops / min or more), pain may appear along the veins, passing with a decrease in the rate of administration.

In patients with a modified venous wall as a result of prolonged intravenous infusions, an irritating effect of carnitine is possible, which significantly decreases with a greater degree of its dilution.

drug interaction

GCS, when used together with carnitine, contributes to its accumulation in tissues (except the liver).

Anabolic drugs enhance the effect.

Dosage of carnitine chloride

In / in, drip slowly (no more than 60 drops / min). Before the introduction of the contents of 1 or 2 amp. - 5-10 ml (0.5-1 g) - diluted in 200 ml of 0.9% sodium chloride solution for injection.

In acute disorders of cerebral circulation, it is prescribed in the first 3 days, 1 g 1 time per day, and then for 7 days, 0.5 g / day. After 10-12 days, repeated courses are recommended - 0.5 g 1 time per day. day for 3-5 days.

When prescribing the drug in the subacute and recovery periods, with dyscirculatory encephalopathy and various brain lesions, patients are administered 0.5-1 g (1-2 amps) of the drug 1 time per day for 3-5 days. If necessary, a second course is prescribed after 12-14 days.

Overdose

Cases of overdose are unknown.

Precautionary measures

It can be used for anorexia, malnutrition, growth retardation in children.

• Instructions for use Carnitine chloride
• Ingredients of Carnitine Chloride
• Indications for carnitine chloride
• Storage conditions of the drug Carnitine chloride
• Shelf life of the drug Carnitine chloride

Release form, composition and packaging

5 ml - ampoules (5) - blister packs (1) - cardboard packs.
5 ml - ampoules (5) - blister packs (2) - cardboard packs.

Description medicinal product CARNITINE CHLORIDE was created in 2010 on the basis of instructions posted on the official website of the Ministry of Health of the Republic of Belarus. Date of update: 08/03/2011

pharmachologic effect

Stimulates metabolic processes, participating in various parts of energy metabolism. It has anabolic, antihypoxic and antithyroid effects, activates fat metabolism, stimulates regeneration, increases appetite. Carnitine is a natural substance related to B vitamins. It is a cofactor in metabolic processes that maintain CoA activity. Reduces basal metabolism, slows down the breakdown of protein and carbohydrate molecules. Promotes penetration through mitochondrial membranes and cleavage of long-chain fatty acids (palmitic, etc.) with the formation of acetyl-CoA, which is necessary to ensure the activity of pyruvate carboxylase in the process of gluconeogenesis, the formation of ketone bodies, the synthesis of choline and its esters, oxidative phosphorylation and the formation of ATP. Mobilizes fat (the presence of 3 labile methyl groups) from fat depots. Competitively displacing glucose, it includes a fatty acid metabolic shunt, the activity of which is not limited by oxygen (unlike aerobic glycolysis), and therefore the drug is effective in acute hypoxia (including the brain) and other critical conditions. It has a neurotrophic effect, improves protein and fat metabolism, increased basal metabolism in thyrotoxicosis (being a partial thyroxine antagonist). It restores the alkaline reserve of the blood, does not affect the blood coagulation system, reduces the formation of keto acids, increases the resistance of tissues to the influence of toxic decay products, activates anaerobic glycolysis, has antihypoxic properties, stimulates and accelerates reparative processes.

Pharmacokinetics

3 hours after intravenous administration, it is almost completely eliminated from the blood. Easily penetrates into the liver and myocardium, more slowly - into the muscles. It is excreted by the kidneys mainly in the form of acyl esters.

Indications for use

The drug is prescribed alone or as part of complex therapy for:

• acute disorders of cerebral circulation (ischemic stroke, transient ischemic attack);
• dyscirculatory encephalopathy and various traumatic and toxic lesions of the brain;
• primary (genetic) and secondary carnitine deficiency (including in patients with chronic renal failure on hemodialysis);
• cardiomyopathy, myocarditis, coronary disease heart (angina pectoris, acute myocardial infarction, post-infarction conditions), cardiogenic shock;
• in the treatment of cytostatics, especially anthracyclines (as a cardioprotector);
• growth retardation in children.

Dosing regimen

In / in drip slowly (no more than 60 drops per minute!). Before administration, every 100 mg of the drug (1 ml of a 10% solution) is dissolved in 50 ml of an isotonic sodium chloride solution of 0.9% or 5% glucose solution.

In the acute period of ischemic stroke, transient ischemic attack, traumatic or toxic brain damage in the first 3 days, 10-14 mg/kg of the patient's body weight is administered, in the following days - 7 mg/kg of the body weight. The general course of treatment is 7-10 days. If necessary, after 10-12 days, a second course of 7 mg / kg of body weight is carried out for 3-5 days.

When prescribing a drug in subacute and recovery periods of dyscirculatory encephalopathy and various brain lesions patients are administered 500-1000 mg of carnitine chloride once a day for 3-5 days. If necessary, a second course is prescribed after 12-14 days.

At secondary deficiency carnitine during hemodialysis - in / in, at a dose of 2 g / day after a hemodialysis session.

At acute myocardial infarction the daily dose is 100-200 mg / kg of body weight in the form of 4 slow intravenous injections or continuous intravenous administration for the first 48 hours, followed by a dose reduction by 2 times. Next, you should switch to oral carnitine.

At cardiogenic shock in / in the introduction should be continued until the exit from this state.

Children: initial dose - 50 mg / kg / day, slowly over 2-3 minutes, as an intravenous injection or continuous infusion, maintenance dose - 50 mg / kg / day, every 3-4 hours, at least 4 times a day day;

Side effects

allergic reactions, muscle weakness in patients with uremia. With rapid administration (80 drops / min or more), pain may occur along the vein, passing with a decrease in the rate of administration.

special instructions

The drug is used with caution in patients with aggravated allergic anamnesis. Since carnitine improves the absorption of glucose, it is necessary to control its level in the blood serum in patients with diabetes mellitus.

Pregnancy and lactation. Special studies on the study of the possibility of use during pregnancy and lactation have not been conducted. When prescribing during these periods, the benefit to the mother and the potential risk to the fetus or child should be carefully weighed. It is believed that carnitine deficiency during pregnancy poses a significantly greater risk to the mother than the theoretical risk to the fetus. Carnitine is a natural component of breast milk, but studies on the efficacy and safety of carnitine use during lactation have not been conducted.

Features of the effect of the drug on the ability to drive a vehicle or potentially dangerous mechanisms. Persons who report muscle weakness after taking carnitine should refrain from driving and potentially dangerous machinery.